Changsha Evening News, December 1 (Quan** reporter Yue Xia, correspondent Ding Lexi, Yan Li) In 2022, "the pathogenesis of 'ferroptosis' and glaucoma will be revealed for the first time in the world" and "original results of optic nerve protection of glaucoma will be published";In 2023, "breakthroughs in the pathogenesis and optic nerve protection of glaucoma" ......This is one breakthrough after another made by Professor Xia Xiaobo's team at the Ophthalmology Center of Xiangya Hospital of Central South University and the Hunan Provincial Key Laboratory of Ophthalmology in the past two years.
These research results have allowed human beings to advance the distance from passive single defense to active multi-party prevention inch by inch in the face of blinding diseases such as glaucoma, and grasp the initiative step by step. With 35 years of medical experience, Professor Xia Xiaobo has been struggling with problems in the field of ophthalmology and leading the team to be the ultimate catcher of "vision killers".
What is currently difficult is the early diagnosis of glaucoma".
In the most popular terms, Professor Xia Xiaobo's team is studying the early diagnosis and treatment of glaucoma and cataracts. "Early detection and early **" is the goal of glaucoma researchers.
Glaucoma is the world's first irreversible blinding eye disease, with complex and uncertain causes, and a single drug. "It is expected that by 2040, there will be more than 100 million glaucoma patients in the world, so the ** of glaucoma has attracted the attention of global ophthalmology experts. Professor Xia Xiaobo said that the current difficulty is the early diagnosis of glaucoma, eye swelling pain, rainbow vision, foggy vision are mild symptoms of glaucoma, which are easy to be ignored by patients, and most patients are treated only when the visual field becomes smaller, which is already the advanced stage of glaucoma.
Professor Xia Xiaobo introduced that reducing pathological ocular hypertension in glaucoma patients through drugs or surgery is the only effective method for glaucoma in clinical practice, but simply controlling pathological intraocular hypertension cannot completely prevent the loss of glaucoma retinal ganglion cells (RGCS) RGCS.
These "completely unclear" and "controversial" points are the direction in which Professor Xia Xiaobo led the team forward.
In 2015, Professor Xia Xiaobo's team took the lead in discovering that the iron ion chelator deferoxamine can alleviate the RGCS damage induced by glutamate excitotoxicity, and successively undertook two national natural science projects related to ferroptosis in 2016 and 2021. Professor Xia Xiaobo introduced that in view of the new pathogenesis of glaucoma, the laboratory has successfully developed 2 new targeted nanomedicines, and has applied for relevant invention patents, "In addition, we have also developed 4 new targeted nanomedicines, and relevant experiments have been completed. ”
I ask them to be both good research and good people."
In September this year, 17 Hunan Provincial Key Laboratories, including the Hunan Provincial Key Laboratory of Ophthalmology, received acceptance results as "excellent".
Professor Xia Xiaobo especially praised the backbone of the team and young researchers for "doing both good research and good people", "Our laboratory was only established in 2018, and it is a very young laboratory, including more than 60 doctoral students, involving research in many fields such as glaucoma, retinal diseases, corneal and ocular surface diseases. ”
A good scientist is also a good ophthalmologist. Professor Xia Xiaobo said that the team not only has academician and expert guidance such as Academician Fan Xianqun of Shanghai Jiao Tong University, Professor Chen Xiang of Central South University, and Professor Liu Guoguo of Xiamen University, but also a group of young and promising medical workers.
Recently, the original translational medicine work of Professor Xia Xiaobo's team from the Ophthalmology Center of Xiangya Hospital of Central South University and the Hunan Provincial Key Laboratory of Ophthalmology "Targeting the cell membrane, depleting ROS through the polymer of disulfide and thioone bonds, and carrying cholesterol molecules to deliver necrostatin ** glaucoma", was officially published in the American "ACS Nano" with Rong Rong, a doctoral student from the Eye Center of Xiangya Hospital, Central South University, and Zhou Xuezhi, a postdoctoral fellow, as the co-first authorsIn the field of oxidative stress, the world's top journal "Redox Biology" published an original academic paper "transporter 18kda regulates glaucoma retinal neuronal apoptosis and pyroptosis", and Zeng Zhou, You Mengling, doctoral students of the Eye Center of Xiangya Hospital, Central South University, and Rong Rong, a distinguished associate professor, are the co-first author......s
In the introduction of the first author, Rong Rong, who had just graduated with a doctorate, immediately had a change in identity, and she had been specially hired as an associate professor by the hospital.
In addition to cultivating young backbones, the ophthalmology laboratory has also hosted the Xiangya International Ophthalmology Forum for many times, and the national continuing medical education program Xi and training courses, with a total of more than 100,000 online and offline participants, and more than 1,000 ophthalmology talents have been trained.
Every day, I feel happy to relieve the pain of the patient."
In terms of administrative positions, he is the vice president of Xiangya Hospital of Central South University;In terms of scientific research, he is the director of the Hunan Provincial Key Laboratory of OphthalmologyClinically, he is the chief physician and professor of ophthalmology, and he has outpatient clinics twice a week and several surgeriesPoverty alleviation at the grassroots level and technical support ......From 7 a.m. to 12 p.m., seven days a week, this kind of work intensity is not unbearable for Professor Xia Xiaobo, all because of "love" and indulging in the joy of doctors - "From graduating in 1988 to the present, I have been working on the medical front for 35 years. It is a very honorable thing to study medicine and protect people's lives and health. My professional experience is that every day I do good deeds and alleviate the pain of patients, so I don't feel tired and feel happy after working for fifteen or sixteen hours. ”
As the first "Xiangya Famous Doctor" of Central South University, Professor Xia Xiaobo not only often conducted guidance exchanges in China, but also led the team to Myanmar and Pakistan for surgery and technical guidance, and completed 159 free cataract surgeries during the four-day event in Myanmar, diagnosing and treating hundreds of patients with eye diseases. "We not only bring light to the people of Myanmar, but also share the standard cataract surgery procedures and surgical techniques with local medical staff, which promotes the exchange and development of ophthalmology academics. He said.
For the future, the Hunan ophthalmology research and clinical leader has more expectations: "We are narrowing the gap with developed countries, and we need to continue to work hard in the future, increase funding and focus on talent cultivation." ”
At present, Xiangya Hospital of Central South University has been successfully selected as a comprehensive national medical center, and a new hospital is being built in Tianxin District. According to the positioning of the National Medical Center, Xiangya Hospital will make greater achievements in the research and development of new technologies and new products, as well as the transformation of achievements and clinical applications.